On 27 March 2017, France went one step further than other countries by adopting “hard” law on human rights with the very broad Law on the “duty of vigilance of the parent companies and main contractor companies”. This statute is now into force and the first “vigilance plans” are being published as companies file their
On 19 January 2017, major modifications were adopted in France to the regulations on interactions between the industry and healthcare professionals (and other stakeholders). These new regulations, a.k.a. “anti-benefits regulations”, will entail major changes in the industry’s compliance procedures relating to payments and other transfers of value to those stakeholders. The new rules are
Japan recently renewed interest in constructing advanced nuclear reactors domestically.
In France, anti-benefits regulations prohibit the health industry from offering direct and indirect benefits of any kind to HCPs, except in very limited circumstances. These regulations also establish a consultative process requiring the prior opinion of professional bodies, in particular on the fair market value of payments made to HCPs. These regulations apply to companies
On 5 July 2012, Medicines Australia, the pharmaceutical industry association in Australia, announced the adoption of its new Code of Conduct. Although the Code is not legally binding, it reflects a growing tendency, partly legislative in nature and partly through industry self-regulation, to promote transparency in relationships between the pharmaceutical industry and healthcare professionals and